• Haeder Abdulhafith Al-biati Department of Clinical Pharmacy, College of pharmacy, University of Bagdad, Iraq
  • Ahmed Salih Sahib Department of Pharmacology, College of Pharmacy, University of Kerbala, Iraq
  • Anwar Noori Mahmood Department of Surgery, Baquba Teaching Hospital, Diyala, Iraq




Breast cancer, Postmenopausal, Vitamin D, Estradiol


Objective: Obesity is associated with both increased breast cancer risk and poorer prognosis after disease onset. Women who are obese continue to have higher levels of estrogen than women of normal weight even after treatment with hormone-suppressing drugs, raising the possibility that they might benefit from modification or changes to their treatment. The aim of this work was to study the effect of letrozole compared to tamoxifen on serum estradiol and, vitamine D and metabolic profile in Iraqi obese postmenopausal women with breast cancer.

Methods: A hospital-based case-control study was carried out at Baquba teaching hospital, Diyala, Iraq. The analyzed variables were: age, lipid profile including total cholesterol; triglycerides, HDL-C, blood sugar, estradiol, and serum vit D. Descriptive statistics and testing of hypothesis were used for the analysis using mean±SD test P≤0.05.

Results: Lipid profile, serum estradiol showed significant variability among the studied group in this study and serum vit D show significant differences between groups in postmenopausal obese with breast cancer taking tamoxifen.

Conclusion: Treatment of obese women with breast cancer with tamoxifen or letrozole had neglected effects on metabolic parameters including lipid profile and blood sugar, both agents decrease serum estradiol level in treated patients, and most importantly, the significant positive effect of tamoxifen on serum vitamin D level compared to negative effect of aromatase inhibitor drug letrozole.


Download data is not yet available.


Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC. Early breast cancer. Lancet 2009;373:1463-79.

Brandt A, Bermejo JL, Sundquist J, Hemminki K. Age of onset in familial breast cancer as background data for medical surveillance. Br J Cancer 2010;102:42-7.

Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, et al. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer 2005;6:391-401.

Iraqi Cancer Board. Results of the Iraqi Cancer Registry 2004. Baghdad, Iraqi Cancer Registry Center, Ministry of Health; 2007.

Doyle SL, Donohoe CL, Lysaght J, Reynolds JV. Visceral obesity, metabolic syndrome, insulin resistance and cancer. Proc Nutr Soc 2001;3:1–9.

Welsh J. Vitamin D and breast cancer: insights from animal models. Am J Clin Nutr 2004;80:1721–4S.

Arora H, Dixit V, Dhanwal D, Srivastava N. Vitamin D, an evidence based medicine. Innovare J Med Sci 2016;4:19-20.

Goyal A, Verma A, Kaur R, Kamboj A, Jain JK. The beneficial effect of vitamin D on high-fat diet-induced obesity in wistar rats. Asian J Pharm Clin Res 2016;9:337-40.

Mehta RG, Mehta RR. Vitamin D and cancer. J Nutr Biochem 2002;13:252–64.

Garrett A, Quinn MA. Hormonal therapies and gynaecological cancers. Best Pract Res Clin Obstet Gynaecol 2008;22:407–21.

Gould RE, Garcia AA. Update on aromatase inhibitors in breast cancer. Curr Opinion Obstetrics Gynecol 2006;18:41–6.

Gowal S, de Giacoms M, Le Boudec JY. A validated mathematical method of cell mediated immune response to tumor growth. Cancer Res 2007;67:8419-21.

Wade GN, Heller HW. Tamoxifen mimics the effects of estradiol on food intake, body weight, and body composition in rats. Am J Physiol 1993;264:R1219-23.

Wallen WJ, Belanger MP, Wittnich C. Sex hormones and the selective estrogen receptor modulator tamoxifen modulate weekly body weights and food intakes in adolescent and adult rats. J Nutr 2001;131:2351-7.

Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al., Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-5.

Ozet A, Arpaci F, Yilmaz MI, Ayta H, Ozturk B, Komurcu S, et al. Effects of tamoxifen on the serum leptin level in patients with breast cancer. Japan J Clin Oncol 2001;31:424-7.

Günel N, Coşkun U, Toruner FB, Sancak B, Yilmaz E, Cengiz O, et al. Serum leptin levels are associated with tamoxifen-induced hepatic steatosis. Curr Med Res Opin 2003;19:47-3.

López M, Lelliott CJ, Tovar S, Kimber W, Gallego R, Virtue S, et al. Tamoxifen-induced anorexia is associated with fatty acid synthase inhibition in the ventromedial nucleus of the hypothalamus and accumulation of malonyl-Co A. Diabetes 2006;55:1327-36.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al., Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41.

Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 1996;10:905-12.

Love R, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852–6.

Vestergaard P, Rejnmark L, Mosekilde L. Effect of tamoxifen and aromatase inhibitors on the risk of fractures in women with breast cancer. Calcif Tissue Int 2008;82:334–40.

Shapiro CL. Aromatase inhibitors and bone loss: risks in perspective. J Clin Oncol 2005;23:4847–9.

Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003;348:2431–42.



How to Cite

Al-biati, H. A., A. S. Sahib, and A. N. Mahmood. “EFFECTS OF TAMOXIFEN OR LETROZOLE ON LIPID PROFILE, VITAMIN D AND ESTRADIOL SERUM LEVELS IN OBESE POSTMENOPAUSAL WOMAN WITH BREAST CANCER”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 9, no. 2, Feb. 2017, pp. 142-4, doi:10.22159/ijpps.2017v9i2.14918.



Original Article(s)